Privium Fund Management’s Axsome Therapeutics AXSM Stock Holding History

Privium Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.93M	Buy	58,729 +1,851	+3%	+$320K	2.07%	15
2025 Q4	$10.4M	Buy	56,878 +4,146	+8%	+$579K	1.91%	17
2025 Q3	$6.4M	Hold	52,732	–	–	1.15%	17
2025 Q2	$5.43M	Hold	52,732	–	–	1.17%	14
2025 Q1	$6.15M	Sell	52,732 -9,500	-15%	-$1.08M	1.6%	14
2024 Q4	$5.27M	Sell	62,232 -18,000	-22%	-$1.66M	1.19%	18
2024 Q3	$7.21M	Buy	80,232 +5,900	+8%	+$515K	1.79%	16
2024 Q2	$5.87M	Sell	74,332 -7,700	-9%	-$570K	1.5%	20
2024 Q1	$6.55M	Buy	82,032 +10,000	+14%	+$839K	1.75%	17
2023 Q4	$5.55M	Hold	72,032	–	–	1.55%	22
2023 Q3	$5.03M	Hold	72,032	–	–	1.5%	20
2023 Q2	$5.27M	Sell	72,032 -87,442	-55%	-$6.45M	1.52%	19
2023 Q1	$9.84M	Buy	+159,474	New	+$10.5M	3.3%	8

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Privium Fund Management's AXSM Position: Q1 2026 in Review

Privium Fund Management increased its Axsome Therapeutics (AXSM) stake by 3.3% in Q1 2026, buying an estimated $320K and bringing the position to 58,729 shares worth $9.93M. The position accounts for 2.07% of the portfolio, ranked #15.

Privium Fund Management first reported a position in AXSM in Q1 2023 and has held it in 13 quarters since. The position peaked at $10.4M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Privium Fund Management held 58,729 shares of Axsome Therapeutics worth $9.93M as of Q1 2026.
Privium Fund Management bought 1,851 Axsome Therapeutics shares in Q1 2026, an estimated $320K.
Axsome Therapeutics made up 2.07% of Privium Fund Management's portfolio in Q1 2026, its #15 holding.
Privium Fund Management first reported a position in Axsome Therapeutics in Q1 2023 and has held it in 13 quarters since.
Privium Fund Management's Axsome Therapeutics position peaked at $10.4M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.